The approval introduces a new approach to reducing the risk of recurrent stroke, supported by results from a Phase III trial involving more than 12,000 patients.
The FDA approved Bayer’s Sunharbo (asundexian) on November 9, 2026, making it the first Factor Xla inhibitor approved in the US.
The once-daily oral drug is indicated for use alongside antiplatelet therapy to reduce the risk of stroke in adults who have recently experienced a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA), often called a “mini-stroke”.
A non-cardioembolic ischemic stroke occurs when a blood clot that did not originate in the heart blocks blood flow to the brain.
Preventing recurring strokes remains a major challenge. According to Bayer, approximately one in 10 stroke survivors experiences another stroke within one year, while one in five experiences another within five years.
The secondary stroke often causes more severe outcomes than the initial stroke.
Unlike existing approaches, Sunharbo works by blocking Factor Xla, a protein involved in blood clotting. This helps reduce thrombin generation, a process involved in clot formation.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Phase III Trial Shows 26% Reduction in Ischemic Stroke Risk
The FDA approval was supported by results from the Phase III OCEANIC-STROKE trial, which enrolled 12,327 adults who had recently experienced a non-cardioembolic ischemic stroke or high-risk TIA.
Participants received either Sunharbo 50 mg once daily or placebo, both alongside antiplatelet therapy.
Over a median treatment period of 14.2 months, Sunharbo reduced the risk of ischemic stroke by 26% compared with placebo. Ischemic stroke occurred in 6.2% of patients receiving Sunharbo versus 8.4% receiving placebo.
Overall major bleeding rates were similar between groups. However, major bleeding was increased among patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding was also more common with Sunharbo, while diarrhea was the most frequently reported adverse reaction.
A New Option for Secondary Stroke Prevention
Sunharbo is not approved for stroke prevention in patients with atrial fibrillation.
Bayer expects the drug to begin shipping in mid-to-late November 2026, with availability for US hospitals and pharmacies shortly afterward.
Bayer is also working to improve access to Sunharbo through its patient assistance program. Eligible patients who cannot afford their prescription may receive the medication at no cost through the Bayer US Patient Assistance Foundation.
Sunharbo received regulatory approval in China on October 26, 2026, and is currently under regulatory review in Europe and Japan.
Beyond Sunharbo, Bayer is advancing research for cardiovascular health.
On November 6-9, 2026, Bayer presented additional findings from the OCEANIC-STROKE trial at the American Heart Association (AHA) Scientific Sessions, alongside research on its drug Kerendia (finerenone) for heart failure and chronic kidney disease.
The approval reflects continued progress in stroke research and efforts to develop new treatment options for improving cardiovascular health.
Other pharmaceutical companies are also investigating Factor Xla inhibitors for stroke prevention.
Bristol Myers Squibb and Johnson & Johnson are developing milvexian, an investigational drug being evaluated in two Phase III trials: LIBERXIA-STROKE, which focuses on preventing recurrent strokes, and LIBREXIA-AF, which examines stroke prevention in patients with atrial fibrillation.
The companies expect to report results from trials in late 2026, which could provide further insights into the potential of Factor Xla inhibitors for anticoagulant therapy.
Join or login to leave a comment
JOIN LOGIN